长江商报奔腾新闻记者 张璐 老牌药企华北制药(600812.SH)延续盈利态势。 8月13日，华北制药披露2025年半年报，公司实现营收52.75亿元，同比增长0.84%；实现净利润1.23亿 元，同比增长71.56%。华北制药表示，营收增长主要得益于市场营销策略的优化和国际化布局的加 速，尤其是重点产品的市场份额扩大。净利润的显著增长则与公司成本控制和市场策略调整紧密相关。 据了解，华北制药是我国最大的制药企业。回顾前几年业绩，公司盈利能力偏弱。2020年-2023年，华 北制药实现的营收分别为114.93亿元、103.85亿元、105亿元、101.20亿元，同比变动幅度为 0.31%、-9.64%、1.11%、-3.62%；净利润分别为0.97亿元、0.19亿元、-6.89亿元、0.05亿元，同比变 动-43.46%、-80.76%、-3780.33%、100.71%； 2024年，华北制药的经营业绩有所好转，实现营收98.7亿元，虽同比下降2.48%，但净利润达到1.27亿 元，同比大幅增长2496.8%。 持续的研发投入也带来了成果。截至今年上半年，华北制药申请发明专利20件；取得授权专利10件，其 ...

Core Viewpoint - North China Pharmaceutical (600812.SH) continues its profitability trend, reporting a revenue of 5.275 billion yuan and a net profit of 123 million yuan for the first half of 2025, marking a year-on-year growth of 0.84% and 71.56% respectively [2][3] Financial Performance - In 2024, the company achieved a revenue of 9.87 billion yuan, a year-on-year decrease of 2.48%, but net profit surged by 2496.8% to 127 million yuan [2] - For the first quarter of 2025, revenue was 2.574 billion yuan, up 0.65%, with net profit reaching 57.49 million yuan, a significant increase of 216.72% [3] Market Strategy - Revenue growth is attributed to optimized marketing strategies and accelerated international expansion, particularly in the Japanese high-end market, with export revenue reaching 1.097 billion yuan, accounting for 20.8% of total revenue [3] - The company has focused on increasing market share for key products, generating 2.77 billion yuan from billion-yuan products [3] R&D Investment - North China Pharmaceutical has consistently prioritized R&D, with expenditures from 2020 to the first half of 2025 totaling 1.309 billion yuan [3] - The company has made significant progress in new product development, completing clinical trials for several generic drugs and obtaining approvals for various pharmaceutical products [3][4] - As of the first half of this year, the company has filed 20 invention patents and received 10 authorized patents, including 8 invention patents [4]